000 | 01929 a2200613 4500 | ||
---|---|---|---|
005 | 20250514020827.0 | ||
264 | 0 | _c20020110 | |
008 | 200201s 0 0 eng d | ||
022 | _a0008-5472 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aLobell, R B | |
245 | 0 | 0 |
_aEvaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. _h[electronic resource] |
260 |
_bCancer research _cDec 2001 |
||
300 |
_a8758-68 p. _bdigital |
||
500 | _aPublication Type: Comparative Study; Evaluation Study; Journal Article | ||
650 | 0 | 4 |
_aAlkyl and Aryl Transferases _xantagonists & inhibitors |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
650 | 0 | 4 |
_aApoptosis _xdrug effects |
650 | 0 | 4 | _aDrug Screening Assays, Antitumor |
650 | 0 | 4 | _aDrug Synergism |
650 | 0 | 4 |
_aEnzyme Inhibitors _xadministration & dosage |
650 | 0 | 4 | _aFarnesyltranstransferase |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aMice |
650 | 0 | 4 | _aMice, Nude |
650 | 0 | 4 |
_aPancreatic Neoplasms _xdrug therapy |
650 | 0 | 4 |
_aProtein Prenylation _xdrug effects |
650 | 0 | 4 | _aTumor Cells, Cultured |
650 | 0 | 4 | _aXenograft Model Antitumor Assays |
650 | 0 | 4 |
_aras Proteins _xmetabolism |
700 | 1 | _aOmer, C A | |
700 | 1 | _aAbrams, M T | |
700 | 1 | _aBhimnathwala, H G | |
700 | 1 | _aBrucker, M J | |
700 | 1 | _aBuser, C A | |
700 | 1 | _aDavide, J P | |
700 | 1 | _adeSolms, S J | |
700 | 1 | _aDinsmore, C J | |
700 | 1 | _aEllis-Hutchings, M S | |
700 | 1 | _aKral, A M | |
700 | 1 | _aLiu, D | |
700 | 1 | _aLumma, W C | |
700 | 1 | _aMachotka, S V | |
700 | 1 | _aRands, E | |
700 | 1 | _aWilliams, T M | |
700 | 1 | _aGraham, S L | |
700 | 1 | _aHartman, G D | |
700 | 1 | _aOliff, A I | |
700 | 1 | _aHeimbrook, D C | |
700 | 1 | _aKohl, N E | |
773 | 0 |
_tCancer research _gvol. 61 _gno. 24 _gp. 8758-68 |
|
999 |
_c11663996 _d11663996 |